Tarsus Pharmaceuticals (TARS) Current Assets (2019 - 2026)

Tarsus Pharmaceuticals' Current Assets history runs 8 years deep, the most recent figure standing at $537.2 million for Q1 2026.

• In Q1 2026, Current Assets rose 11.74% year-over-year to $537.2 million; the TTM figure through Mar 2026 stood at $537.2 million (up 11.74% YoY), while the FY2025 annual figure was $522.8 million, up 46.56% from the prior year.
• Current Assets was $537.2 million for Q1 2026 at Tarsus Pharmaceuticals, up from $522.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $537.2 million in Q1 2026 to a low of $178.8 million in Q1 2022.
• Historically, Current Assets has averaged $337.1 million across 5 years, with a median of $340.7 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Current Assets retreated 26.69% in 2023, then soared 97.62% in 2024.
• A 5-year view of Current Assets shows it stood at $225.4 million in 2022, then rose by 13.65% to $256.1 million in 2023, then jumped by 39.27% to $356.7 million in 2024, then soared by 46.56% to $522.8 million in 2025, then rose by 2.76% to $537.2 million in 2026.
• The last three Current Assets figures came in at $537.2 million (Q1 2026), $522.8 million (Q4 2025), and $501.7 million (Q3 2025), per Business Quant data.